Patents Assigned to Seattle Genetics, Inc.
  • Sensory Apparatus for Detection of Peripheral Neuropathy
    Publication number: 20180085056
    Abstract: A texture ring system is configured to aid individuals in detecting the symptoms of peripheral neuropathy. The system includes planar components that each have a differently textured surface, and a connector component that secures the planar components together in a circular ring.
    Type: Application
    Filed: September 22, 2017
    Publication date: March 29, 2018
    Applicant: SEATTLE GENETICS, INC.
    Inventor: Danya Joy Youngblood
  • Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
    Patent number: 9926376
    Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: March 27, 2018
    Assignees: Agensys, Inc., Seattle Genetics Inc.
    Inventors: Robert Kendall Morrison, Zili An, Karen Jane Meyrick Morrison, Josh Snyder, Xiao-Chi Jia
  • CD19 binding agents and uses thereof
    Patent number: 9919061
    Abstract: This invention relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: March 20, 2018
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
  • COMBINATION THERAPY USING A CD19-ADC AND VINCRISTINE
    Publication number: 20180028681
    Abstract: This invention relates to treatment of acute lymphoblastic leukemia.
    Type: Application
    Filed: February 12, 2016
    Publication date: February 1, 2018
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Che-Leung Law, Ivan Stone
  • DOSAGE AND ADMINISTRATION OF NON-FUCOSYLATED ANTI-CD40 ANTIBODIES
    Publication number: 20170333556
    Abstract: This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
    Type: Application
    Filed: October 29, 2015
    Publication date: November 23, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Shyra Gardai, Che-Leung Law, Stanford Peng, Jing Yang, Haley Neff-LaFord
  • Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
    Patent number: 9816069
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: November 14, 2017
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS
    Publication number: 20170320944
    Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells. Further disclosed is a method of treating multiple myeloma using an anti-NTB-A antibody drug conjugate, which optionally includes an anti-NTB-A antibody as disclosed herein.
    Type: Application
    Filed: June 14, 2017
    Publication date: November 9, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Timothy S. Lewis, Che-Leung Law
  • METHODS FOR SCREENING ANTIBODIES
    Publication number: 20170298118
    Abstract: The invention provides methods for making antibody conjugates for use in antibody screening assays and antibody conjugates produced by the claimed methods.
    Type: Application
    Filed: June 28, 2017
    Publication date: October 19, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Robert Lyon, Dennis Benjamin, Maureen Ryan
  • Humanized antibodies to LIV-1 and use of same to treat cancer
    Patent number: 9783608
    Abstract: The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: October 10, 2017
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Maria Leia Smith, Django Sussman, William Arthur, Albina Nesterova
  • TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES
    Publication number: 20170247412
    Abstract: Compounds and compositions are disclosed in which a quaternized drug unit is linked to a targeting ligand unit from which a tertiary amine-containing drug is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: September 10, 2015
    Publication date: August 31, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Patrick J. Burke, Scott Jeffrey, Joseph Z. Hamilton
  • CYCLODEXTRIN AND ANTIBODY-DRUG CONJUGATE FORMULATIONS
    Publication number: 20170232112
    Abstract: Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine antibody-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine antibody-drug conjugates and process drug-related impurities.
    Type: Application
    Filed: March 9, 2017
    Publication date: August 17, 2017
    Applicant: Seattle Genetics, Inc.
    Inventors: Hui Li, Shan Jiang, Mary Wallace, Damon Meyer
  • BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS
    Publication number: 20170233484
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 17, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • ?-glucuronide-linker drug conjugates
    Patent number: 9731030
    Abstract: Ligand Drug conjugate compounds comprising a ?-glucuronide-based linker and methods of using such compounds are provided.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: August 15, 2017
    Assignee: Seattle Genetics, Inc.
    Inventor: Scott Jeffrey
  • Pyrrolobenzodiazepines used to treat proliferative diseases
    Patent number: 9732084
    Abstract: Pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position on one monomer unit, and a C2-C3 double bond and either a conjugated double or triple bond at the C2 position or an alkyl group at the C2 position on the other monomer unit, and conjugates of these compounds.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: August 15, 2017
    Assignees: Medimmune Limited, Seattle Genetics Inc.
    Inventors: Philip Wilson Howard, Luke Masterson, Arnaud Tiberghien, Scott Jeffrey, Patrick Burke, Peter Senter
  • Methods for screening antibodies
    Patent number: 9725500
    Abstract: The invention provides methods for making antibody conjugates for use in antibody screening assays and antibody conjugates produced by the claimed methods.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: August 8, 2017
    Assignee: Seattle Genetics, Inc.
    Inventors: Robert Lyon, Dennis Benjamin, Maureen Ryan
  • HYDROPHILIC ANTIBODY-DRUG CONJUGATES
    Publication number: 20170216391
    Abstract: Hydrophilic Linkers, Drug-Linker compounds, Drug-Ligand Conjugate compounds and Ligand-Linkers and methods of making and using the same are provided.
    Type: Application
    Filed: February 17, 2015
    Publication date: August 3, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Svetlana Doronina, Robert Lyon, Peter Senter
  • Pyrrolobenzodiazepines and targeted conjugates
    Patent number: 9713647
    Abstract: A compound, or a pharmaceutically acceptable salt or solvate thereof, or conjugates thereof, selected from the group consisting of: wherein: (a) R10 is H, and R11 is OH, ORA, where RA is saturated C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is SOzM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: July 25, 2017
    Assignees: SEATTLE GENETICS, INC., MEDIMMUNE LIMITED
    Inventors: Scott Jeffrey, Patrick Burke, Philip Wilson Howard
  • Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates
    Patent number: 9713648
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: July 25, 2017
    Assignee: Seattle Genetics, Inc.
    Inventors: Eric Sievers, Dana Kennedy
  • Anti-NTB-A antibodies and related compositions and methods
    Patent number: 9708404
    Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells. Further disclosed is a method of treating multiple myeloma using an anti-NTB-A antibody drug conjugate, which optionally includes an anti-NTB-A antibody as disclosed herein.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 18, 2017
    Assignee: Seattle Genetics, Inc.
    Inventors: Timothy S Lewis, Che-Leung Law
  • Pyrrolobenzodiazepines and targeted conjugates
    Patent number: 9707301
    Abstract: This invention relates to pyrrolobenzodiazepines (PBDs), in particular pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position in each monomer unit, and their inclusion in targeted conjugates. The differing substituent groups may offer advantages in the preparation and use of the compounds, particularly in their biological properties and the synthesis of conjugates, and the biological properties of these conjugates.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: July 18, 2017
    Assignees: SEATTLE GENETICS, INC., MEDIMMUNE LIMITED
    Inventors: Scott Jeffrey, Patrick Burke, Philip Wilson Howard